Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant prostate cancer by enhancing the efficacy of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Rushworth, Linda K., Hewit, Kay, Munnings-Tomes, Sophie, Somani, Sukrut, James, Daniel, Shanks, Emma, Dufès, Christine, Straube, Anne, Patel, Rachana, Leung, Hing Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028732/
https://www.ncbi.nlm.nih.gov/pubmed/31844184
http://dx.doi.org/10.1038/s41416-019-0681-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028732/
https://www.ncbi.nlm.nih.gov/pubmed/31844184
http://dx.doi.org/10.1038/s41416-019-0681-5

Ejemplares similares